Vesalius Biocapital et al. back ProFibrix

Existing investors Index Ventures and Gilde Healthcare Partners also participated in the transaction.

In addition to the equity provided by the investors, a government credit took the overall funding round to €15m.

Gilde Health Partners led a previous €8m series-B financing round for ProFibrix in 2009, alongside existing investor Index Ventures.

The fresh capital will be used to advance the company's lead product Fibrocaps into late stage clinical development, as well as to support ProFibrix's other ongoing programs.

Fibrocaps is currently undergoing Phase II trial; if successful, this will lead to a further Phase III trial in early 2012. The company will then file for approval by the US Food and Drug Administration in early 2013.

Company
ProFibrix is a biotechnology company established in 2004. The company develops and markets products for the hemostasis and regenerative medicine markets. Its lead product Fibrocaps is a dry powder topical tissue sealant that stops bleeding after or during surgery.

Headquartered in Leiden, ProFibrix also operates out of Seattle in the US.

People
Alain Parthoens worked on the deal for Vesalius Biocapital.

Dirk Kersten and Francesco De Rubertis represented Gilde Healthcare Partners and Index Ventures respectively.

All three will hold seats on the board of ProFibrix.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Early-stage
• Healthcare
• Netherlands
• Index Ventures
• Gilde Investment Management